Literature DB >> 24498001

Do mismatches between pre- and post-natal environments influence adult physiological functioning?

Tony Robertson1, Michaela Benzeval2.   

Abstract

PURPOSE: Mismatches between pre- and post-natal environments have implications for disease in adulthood. However, less is known about how this mismatch can affect physiological systems more generally, especially at younger ages. We hypothesised that mismatches between pre- and post-natal environments, as measured by the measures of birthweight and adult leg length, would be associated with poorer biomarker levels across five key physiological systems in young adults.
METHODS: Data were collected from 923, 36 year-old respondents from the West of Scotland Twenty-07 Study. The biomarkers were: systolic blood pressure (sBP); forced expiratory volume (FEV1); glycated haemoglobin (HbA1c); glomerular filtration rate (eGFR); and gamma-glutamyltransferase (GGT). These biomarkers were regressed against pre-natal conditions (birthweight), post-natal conditions (leg length) and the interaction between pre- and post-natal measures. Sex, childhood socioeconomic position and adult lifestyle characteristics were adjusted for as potential effect modifiers and confounders, respectively.
RESULTS: There were no associations between birthweight and leg length and sBP, FEV1, HbA1c, or GGT. Higher birthweight and longer leg length were associated with better kidney function (eGFR). However, there was no evidence for mismatches between birthweight and leg length to be associated with worse sBP, FEV1, HbA1c, eGFR or GGT levels (P>0.05).
CONCLUSIONS: Our hypothesis that early signs of physiological damage would be present in young adults given mismatches in childhood environments, as measured by growth markers, was not proven. This lack of association could be because age 36 is too young to identify significant trends for future health, or the associations simply not being present.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24498001      PMCID: PMC3908925          DOI: 10.1371/journal.pone.0086953

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

The foetal origins of disease have been widely studied, with pre-natal growth (often measured through birthweight and used as a marker for the uterine developmental environment) consistently linked with the later development of adult disease [1]. However, there is mounting evidence that the association between pre-natal development and later health is strengthened when post-natal conditions are considered. Typically, poorer growth in utero (as a result of, for example, poor nutrition, maternal smoking/alcohol consumption or maternal stress) [2] followed by rapid growth in childhood (as a result of, for example, increased nutrition, reduced stress or decreased infections) [3] appears to have the greatest detrimental effect on health [4]–[7]. Although there is increasing evidence of the implications for disease in adulthood following such plasticity in growth brought about by mismatches in environmental circumstances, less is known about how mismatches could affect the physiological systems in the body more generally, especially at younger ages. This relationship is important as it could improve not only our understanding of the early-life influences on disease process, but also enable earlier intervention prior to the onset of disease. The aim of this study was to examine the influence of mismatches between pre- and post-natal conditions across five key physiological systems important to health and functioning. The biomarkers selected were: systolic blood pressure (sBP; circulatory system); forced expiratory volume in one second (FEV1; respiratory system/lung function); glycated haemoglobin (HbA1c; metabolic system/diabetes marker); estimated glomerular filtration rate (eGFR; excretory system/kidney function); and gamma-glutamyltransferase (GGT; hepatic system/liver function). We chose to focus on young adults to identify effects prior to the onset of disease. Our hypothesis was that mismatches between birthweight and leg length (marker of post-natal childhood environment and growth [8]–[10]) would be associated with more negative biomarker outcomes, with the association strongest with GGT given that the liver is one of the most plastic organs after birth [5]. There is evidence that post-natal conditions continue to influence sBP [11], [12] and HbA1c [11], [13]. We predicted that there would be an association between those respondents showing mismatches between pre- and post-natal conditions and these two biomarkers, although weaker than that seen with GGT (due to their reduced plasticity in childhood). The evidence for an association between mismatches between pre- and post-natal conditions and FEV1 is weaker than for BP and HbA1c [14], [15]. Therefore it was predicted that mismatches between pre- and post-natal conditions would be only weakly associated with FEV1. It was predicted that eGFR would not be associated with mismatches between pre- and post-natal conditions given that kidney development is complete prior to birth [16], [17].

Methods

Study Sample

The West of Scotland Twenty-07 Study is a community-based, prospective cohort study started in 1987 and completed in 2007/8. Individuals were recruited using a clustered randomised sample design in the greater Glasgow area in the West of Scotland, UK. Respondents were aged 36 years at blood sampling (wave 5 of data collection). The baseline sample consisted of 1515 respondents (777 women). Due to attrition, the sample size by wave 5 was 923 (505 women). Data were collected by trained nurses in participants’ homes. More detail about the study is available elsewhere [18].

Main Outcome Measures

Systolic BP (mmHg) was measured using a sphygmomanometer (Omron Healthcare UK Ltd., West Sussex, UK). The mean values of two readings from the same arm were used. FEV1 (litres/second) was measured using a vitalograph (Micro Plus Spirometer MS03; Micro Medical, Rochester, UK). The highest value of three readings was used, standardised by dividing by height squared [19]. Serum creatinine (µmol/l) was measured using the Kinetic Jaffe method (list number 7D64, Abbott Diagnostics, Abbott, Illinois, USA). Creatinine was standardised to produce eGFR (ml/min) using the Cockcroft-Gault method [20]. Serum GGT (units/litre) was measured using the carboxyl nitroanilide (IFCC) method (list number 7D65, Abbott Diagnostics). Whole blood HbA1c (%) was measured using an HPLC auto-analyser method (HA-8160; Menarini, Rungis, France). In analyses using BP and HbA1c, we identified the need to employ adjustments to the statistical models to address potential modifying effects of medications on biomarkers. For those respondents using anti-hypertensive (n = 24) or anti-diabetes (n = 7) medications we included dummy variables for medication use in the statistical models [21] [22]. As a sensitivity test, we also excluded these individuals from the analysis. The results were unchanged.

Growth Measures

The parents of respondents were asked at baseline to recall the birthweight (kg) of the respondent. Leg length was derived from subtracting sitting height (cm) from standing height (cm) at age 36, both measured using a Seca Leicester stadiometer (Cranlea, Birmingham, UK). Each growth marker was standardised using sex-specific z-scores prior to analysis.

Lifestyle Factors and Socioeconomic Position

Lifestyle factors can alter the physiology and biomarker levels of people throughout their lives. Given this potential for confounding the association between early-life factors and later biomarker measures, we chose to adjust for alcohol and smoking consumption, as well as obesity and physical activity. Data on alcohol consumption (units/week), smoking status (‘current’, ‘ex’ or ‘never’ smoker), Body Mass Index (BMI) and physical activity (hours of moderate or vigorous activity/week) were collected at wave 5. Childhood socioeconomic position (SEP) is linked with both birthweight and growth in childhood, with lower SEP children showing lower birthweight [23], but greater levels of compensatory/catch-up growth in early childhood [24]. In addition, SEP is strongly linked with disparities in adult health and physiological functioning [25]. Hence, we also investigated childhood SEP as a potential effect modifier through stratified analysis, using occupation-based social class at birth (Registrar General’s Social Class). The highest ranking occupation between the two parents was selected.

Statistical Analysis

A total of 768 respondents had complete data for birthweight, leg length, parental occupation and the lifestyle characteristics. All 768 respondents had their blood pressure recorded, but only 749 had FEV1 measured. 644 respondents provided blood samples suitable for measurement of HbA1c, with 643 providing eGFR and GGT results. The total amount of missing data across all measures was 6% for those taking part in wave 5 and 31% when all those respondents who were in the study at baseline were considered. Multiple imputation (MI) was used to address potential biases arising from missing data values. Twenty five imputed datasets were created. Imputation and analyses were performed using the ‘ice’ and ‘mim’ packages in Stata (ver.11, Stata Corp., Texas, USA). In addition to all variables used in the analyses, auxiliary variables (those not included in the analysis, but which help predict missingness) were also included in the imputation model. These included ‘any chronic illness’ and ‘self-rated health’ at wave 5, and ‘mother’s religion’, ‘whether breastfed’, ‘any birth complications’ and ‘any limiting longstanding illness in the household’ at wave 1. Linear regression was used for the statistical analyses, with all analyses adjusted for clustered sampling at baseline and were weighted to the living baseline sample at the time of the wave 5 interviews using inverse probability weights to correct for bias due to drop out [26]. These weights were also included in the imputation model. Separate analyses were run for each biomarker. For clearer interpretation of the results, higher levels of all five biomarkers reflect poorer functioning. For FEV1 and eGFR, results were multiplied by −1 prior to regression analysis to reflect this. The initial (‘unadjusted’) models included: birthweight, leg length and birthweight*leg length (used to assess the mismatch between pre- and post-natal growth measures [27]), all assessed as continuous variables; sex; and birth status (singleton or twin). The ‘adjusted’ models additionally included the adult lifestyle factors. The different lifestyle confounders were tested separately, although only the fully adjusted models (all confounders included) are presented due to a lack of substantive differences compared to the single-confounder models. Sub-sample analyses, stratifying by sex and SEP, were also run to investigate possible effect modification, but again showed no substantive differences compared to the full models. All analyses were weighted to the living baseline sample at the time of the wave 5 interviews using inverse probability weights to correct for bias due to drop out [26].

Sensitivity Analysis

Categorical versions of birthweight and leg length were also considered in order to capture more extreme cases of the mismatch between pre- and post-natal growth. Birthweight was categorised as low (<2.5 kg), average (2.5–3.9 kg) or high (>3.9 kg), while leg length was converted into sex-specific tertiles. Regression analyses using a nine-category variable were employed, with those showing low birthweight and long leg length used as the reference category.

Ethical Approval

Ethical approval for the baseline study was granted in 1986 by the GP Sub-Committee of Greater Glasgow Health Board and the ethics sub-committee of the West of Scotland Area Medical Committees. Wave 5 was approved by the Tayside Committee on Medical Research Ethics. Informed, written consent was obtained from all respondents at each wave of the study. At wave 1 (when aged 15), written consent was obtained from parents/guardians and the respondents.

Results

The characteristics of the respondents sampled are shown in Table 1. Birthweights were comparable to the national average in 1985 [28], as were lifestyle factors compared to national data from 2011 [29]. Biomarker values were largely below clinically-relevant cut-offs. Analysis samples were similar to the complete wave 5 sample in terms of proportions within each category and mean values (not presented). The results of the analyses are presented in Table 2, where a significant negative coefficient represents a scenario where small birthweight would have a greater effect only in those with longer leg length [27]. A significant positive interaction would suggest that increasing birthweight would have a greater effect only in those with longer leg length. However, there was no evidence that mismatches between pre- and post-natal conditions were associated with any of the five biomarkers, either before or after adjustment for adult lifestyle factors (Table 2). Complete-case analysis results did not reveal any substantive differences to those presented using MI (Table S1 in File S1). Analysis of the individual growth markers (birthweight and leg length) also failed to show any associations with sBP, FEV1, HbA1c or GGT. However, higher birthweight was associated with better kidney function (eGFR) (β = −5.45, 95% CI: −8.53, −2.38), with this association remaining after adjustment for lifestyle confounders (β = −2.95, 95% CI: −5.04, −0.87). Greater leg length was also associated with better kidney function, but only after adjustments (β = −5.35, 95% CI: −7.89, −2.81). The results of the sex and SEP-stratified analyses were no different from the full analyses.
Table 1

Study characteristics based on those taking part in wave 5 (non-imputed).

SamplesizeMean (SD)
Sex 923
Male418 (45.3%)
Female505 (54.7%)
Missing 0 (0%)
Birthweight (kg) 877 3.31 (0.60)
Missing 46 (5.0%)
Leg length (cm) 906 79.52 (6.10)
Missing 17 (1.8%)
sBP (mmHg) 917 124.45 (15.87)
Missing 6 (0.7%)
FEV1 (litres/sec)/height2 879 1.18 (0.19)
Missing 44 (4.8%)
HbA1c (%) 757 5.21 (0.49)
Missing 166 (18.0%)
eGFR (ml/minute) 752 116.00 (28.82)
Missing 171 (18.5%)
GGT (units/litre) 756 35.46 (39.76)
Missing 167 (18.1%)
Weekly alcohol consumption * 848
Not heavy drinker592 (62.9%)
Heavy drinker256 (27.2%)
Missing 93 (9.9%)
Smoking status 918
Never smoked443 (47.1%)
Ex-smoker217 (23.1%)
Current smoker258 (27.4%)
Missing 23 (2.4%)
BMI 896
Underweight (<18.50)12 (1.3%)
Normal range (18.50–24.99)278 (29.5%)
Overweight (25.00–27.49)356 (37.8%)
Obese (≥30.00)250 (26.6%)
Missing 45 (4.8%)
Weekly physical activity ** 918
Below recommended levels* 556 (59.1%)
Meet or surpass recommended levels* 362 (38.5%)
Missing 23 (2.4%)
Social class at birth (SEP) 892
I (Professional etc. occupations)84 (9.1%)
II (Managerial and technical occupations)184 (19.9%)
III – NM (Non-manual skilled occupations)345 (37.4%)
III – M (Manual skilled occupations)178 (19.3%)
IV (Partly-skilled occupations)92 (10.0%)
V (Unskilled occupations)9 (1.0%)
Missing 31 (3.4%)

Heavy drinker = more than 14 (women) or 21 (men) units per week.

Based on the UK Departments of Health recommendations of 2.5 hours of moderate or 1.25 hours of vigorous activity per week for 18–64 year olds.

Table 2

Regression results for the five biomarkers modelled against birthweight and leg length.

Multiple imputation analysis (n = 923)
UnadjustedAdjusted
β95% CIβ95% CI
BP- Birth weight−0.10−1.12, 0.92−0.57−1.58, 0.42
- Leg length−0.35−1.94, 1.250.66−0.74, 2.07
- Birth weight*Leg length0.41−0.49, 1.310.14−0.66, 0.94
FEV1 - Birth weight−0.02−0.03, 0.01−0.01−0.03, 0.01
- Leg length−0.01−0.02, 0.020.01−0.01, 0.03
- Birth weight*Leg length0.01−0.01, 0.020.01−0.01, 0.02
HbA1c - Birth weight−0.02−0.058, 0.03−0.03−0.08, 0.03
- Leg length−0.05−0.11, 0.010.04−0.10, 0.03
- Birth weight*Leg length0.01−0.04, 0.060.01−0.05, 0.06
eGFR- Birth weight−5.45−8.53, −2.38** −2.95−5.04, −0.87**
- Leg length0.93−3.97, 2.11−5.35−7.89, −2.81**
- Birth weight*Leg length−0.52−4.39, 3.35−0.30−2.28, 2.88
GGT- Birth weight−3.36−7.88, 2.33−3.82−7.70, 0.06
- Leg length−4.92−10.05, 1.17−3.32−8.81, 2.18
- Birth weight*Leg length0.12−3.96, 4.21−0.48−4.70, 3.75

p≤0.05;

p≤0.001.

Unadjusted: models include sex and birth status (singleton or twin).

Adjusted: models include unadjusted model plus: alcohol, smoking consumption, BMI, physical activity.

Heavy drinker = more than 14 (women) or 21 (men) units per week. Based on the UK Departments of Health recommendations of 2.5 hours of moderate or 1.25 hours of vigorous activity per week for 18–64 year olds. p≤0.05; p≤0.001. Unadjusted: models include sex and birth status (singleton or twin). Adjusted: models include unadjusted model plus: alcohol, smoking consumption, BMI, physical activity. The sensitivity analysis using a nine-category version of growth marker mismatches revealed that there were no consistent associations with any of the five individual biomarkers Tables S2a–S2e in File S1).

Discussion

This study found that mismatches between pre- and post-natal conditions, represented as the interaction between birthweight and leg length in adulthood, were not associated with worse physiological functioning across the circulatory (sBP), respiratory (FEV1), metabolic (HbA1c), excretory (eGFR) and hepatic (GGT) systems in 36-year-old men and women from the West of Scotland. These findings did not match our hypotheses for sBP, HbA1c or GGT, although they did match our predictions for a lack of association with FEV1/eGFR. The evidence linking mismatches between pre- and post-natal conditions and physiological functioning in early adulthood has received limited attention. Of those studies that have investigated the issue, there have been mixed findings brought about by: using a mixture of definitions or methods for operationalising such mismatches; focusing on disease outcomes; focusing solely on either pre- or post-natal growth; incorrectly analysing the interaction between the pre- and post-natal conditions [27]; testing only one biomarker/physiological system; and/or sampling from older respondents only. A recent meta-analysis found that mismatches between pre- and post-natal growth were associated with increased blood pressure in adulthood [30]. Although there is limited evidence for mismatches between pre- and post-natal conditions, as assessed by growth patterns, being linked with HbA1c, they have been linked with increased insulin resistance in 60–79 year-old British women having had low birthweight, but high BMI in childhood [31]. In a study of British middle-aged adults, increased birthweight and trunk length were found to be independently associated with increased FEV1, although no interaction was considered [14]. In a study of 60+ year-old British women, increased leg length was associated with lower GGT levels (better functioning). However, to the best of our knowledge, no studies have considered the effects of mismatches between pre- and post-natal growth on GGT. Studies investigating the links between early-life conditions and kidney function/eGFR have focused solely on birthweight due to the major development of the kidney taking place prior to birth, although these have confirmed that lower birthweight is associated with worse kidney outcomes [32]. However, no studies to date have investigated the effects of mismatches between pre- and post-natal growth/conditions on biomarkers across multiple physiological systems. Our hypothesis that early signs of physiological damage (leading to diagnosable diseases later in life) would already be underway in terms of detrimental effects on sBP, HbA1c and GGT levels in young adults given mismatches between pre- and post-natal conditions in childhood has not been confirmed. This lack of association could be the result of several factors. Firstly, age 36 could be too young to identify significant alterations in these biomarkers. Although most diseases linked to the physiological systems represented in this study (such as diabetes and chronic obstructive pulmonary disease (COPD)) do not manifest themselves until 40+ years of age [33], sBP [34], [35], HbA1c [36], [37] and GGT [38], [39] track well from childhood/adolescence through to adulthood. FEV1 [40], [41] and eGFR [42], [43] are also known to track well from early adulthood onwards. Given this lifecourse tracking, we would expect biomarker levels at age 36 to be predictors of biomarker levels (and disease risk) later in adulthood. Secondly, there is the possibility that there truly is no effect of a mismatch between pre- and post-natal conditions on the biomarkers chosen. It was predicted that for eGFR, and FEV1 to a lesser extent, it was unlikely that we would see a significant association with mismatches between pre- and post-natal conditions. However, given the plasticity of GGT in particular, it is surprising that no effect was identified for this biomarker. This study has failed to show any evidence of links between either the pre- or post-natal growth measures with the biomarkers, except for a link between higher birthweight and lower eGFR levels (better kidney function). However, it could be that either pre- or post-natal factors are independent predictors of later outcomes, with the mismatch between the two not being important. Blood pressure is probably the most-studied of the five biomarkers used here for its association with pre-and post-natal growth conditions. There is good evidence for increased blood pressure in those who have experienced growth mismatches in childhood or adolescence (lower birthweight followed by increased height or weight gain later in life) [30], [44]–[46]. However, there is some evidence that the association between birthweight and blood pressure is not robust to confounding factors and is much weaker than previously thought [47]. Indeed, we found no association between birthweight and blood pressure at age 35. In previous studies, lung function has also been found to be associated with growth/environmental mismatches (catch-up growth from a lower birthweight starting point) [48], [49]. A recent meta-analysis also suggested that a 1 kg increase in birthweight was associated with a moderate increase in FEV1 (better lung function) [50]. Similar to blood pressure though, this study found no evidence of such associations. Early life factors relating to diabetes risk later in life have been well studied. [13], [51]–[54]. Forsen et al identified that low birthweight, birth length, ponderal index (mass divided by height3) and placenta weight were associated with increased risk of Type II diabetes [13]. Although height and weight at age 7 were not associated with an increased risk of the disease, rapid (catch-up) growth between ages 7 and 15 and more so when birthweight was low. Eriksson et al added to this by showing that rapid increases in BMI in the first 2 years of life were associated with increased risk of diabetes in adulthood (after age 40), although it was larger babies who had experienced slower growth in the first few months of life who had the greatest risk of the disease [52]. Mericq et al investigated the association between small-for-gestational-age (SGA) babies who showed catch-up growth by age 3 and fasting insulin levels at birth and at age 3 [55]. They found that at birth, SGA babies had lower insulin levels compared to average-for-gestational-age (AGA) babies. However, by age 3 (and after catching up to match the AGA babies), SGA babies had significantly higher insulin levels. Again, our study could find no matching associations. Low birthweight has been found to be associated with reduced kidney size in infants and adults [56]–[58]. Schmidt et al showed that weight at 3 and 18 months of age was positively associated with kidney volume, although there was no evidence of mismatches impacting on kidney volume [58]. Animal models of pre/post-natal mismatches in the form of catch-up growth have shown there to be a “second hit” effect of this plasticity on reducing nephron number [59]. Given that kidney development is complete prior to birth, it is not surprising that no association between the mismatch and eGFR was identified here. However, as one would expect, larger birthweight was associated with improved kidney function. Altered liver function has long been proposed as a mechanism by which poor weight gain in utero is associated with increased CHD risk [60]–[62] through increases in serum cholesterol and plasma fibrinogen levels [61], [63]. However, empirical evidence using biomarkers of liver function are lacking. The third possibility for a lack of association is that more extreme cases of mismatches between pre- and post-natal growth markers are needed to have a measurable effect. Our sensitivity analysis using a categorical variable did not identify any consistent associations with the five biomarkers. This indicates that more extreme mismatches between pre- and post-natal growth are not associated with more detrimental biomarker outcomes. This stayed true even when adjusting for potential confounders, showing the results to be robust. Finally, a lack of statistical power is a potential issue. However, the sample sizes used here are relatively large and should be suitable for identifying statistically significant findings if they exist. Using MI to address the potential for bias due to missing values did not alter any of the results either. MI (and sample weights) cannot fully address issues of selective drop-out however, so the possibility that those individuals with the greatest growth mismatch and/or biomarker scores are missing from wave 5 of the sample must be considered. In this study we have used a relatively large, community-based cohort study, with a wide range of biomarkers across key physiological systems. A further strength of the study is that younger respondents at the age of 36 have been included, with most studies typically focusing on middle- and older-aged adults. This has allowed us to focus on physiological measures relatively early on in adulthood and typically before the diagnosis of chronic diseases. It is important that studies aim to identify the pathways and precursors of disease, rather than focus on disease incidence in mid-later life, in order to help identify at-risk individuals prior to the onset of disease. However, our evidence suggests that even at 36 years of age it may be too early to identify physiological consequences of early-life growth patterns (with individual biomarkers at least). Birthweight is both cheaply and easily measured, as well as being possible to obtain many years after birth. However, it may not represent the best measure for operationalising pre-natal growth, with measures such as body composition and adiposity perhaps more accurate [11], [64], [65]. This study has relied on mothers’ recall of their babies’ birthweight and although not ideal, it has been shown to be comparable to registration data [66]. We also did not have any information regarding gestational age, which could be important in determining if pre-term babies have a distinct link with physiological outcomes in adulthood and if it is these babies who composed our more extreme mismatched group. Leg length represents growth throughout infancy and early childhood [8], [9], so may not be as accurate as a measure of stature/length taken in the first year of life. However, measures of stature were not available for the respondents as infants. Previous studies have typically used BMI or other adiposity measures to assess the interaction between pre- and post-natal conditions. However, leg length can be measured in adulthood as a retrospective measure of post-natal development, especially infant nutrition [10]. In addition, it was not possible to measure BMI in childhood in this sample as the study started when respondents were 15 years old. A trade-off between having biomarker data available in early adulthood and having measures of stature/growth/adiposity during childhood was necessary. The biomarkers chosen were analysed as continuous measures and not converted to clinically relevant (binary) cut-offs. This approach was taken due to the age of the respondents, as most did not show clinically relevant values to justify dichotomising. In addition, it was important for this study that the biomarker measures reflected physiological states prior to the onset of a diagnosable disease in order to help predict disease risk earlier in life. This study has failed to find a conclusive link between mismatches in pre- and post-natal growth and physiological dysregulation across five key bodily systems. However, this does not mean that growth in childhood is not an important determinant of health later in life. Future work could use models of cumulative physiological burden such as allostatic load that combine information across multiple systems in a synergistic fashion [25]. In addition, studies that have more detailed growth measures taken in childhood could also provide more robust indicators of growth and plasticity than achieved here. STROBE Statement: Checklist of items that should be included in reports of cohort. studies (DOCX) Click here for additional data file. Contains Tables S1–S2e. Table S1, Regression results for the five biomarkers regressed against birthweight and leg length (complete-case analysis). Table S2a, Regression results for systolic blood pressure (sBP) by a categorical growth pattern construct. Table S2b, Regression results for Forced Expiratory Volume in one second (FEV1) by a categorical growth pattern construct. Table S2c, Regression results for glycated haemoglobin (HbA1c) by a categorical growth pattern construct. Table S2d, Regression results for estimated Glomerular Filtration Rate (eGFR) by a categorical growth pattern construct. Table S2e, Regression results for gamma-glutamyltransferase (GGT) by a categorical growth pattern construct. (DOC) Click here for additional data file.
  59 in total

1.  Kidney volume, blood pressure, and albuminuria: findings in an Australian aboriginal community.

Authors:  Gurmeet R Singh; Wendy E Hoy
Journal:  Am J Kidney Dis       Date:  2004-02       Impact factor: 8.860

2.  Plasticity and robustness in development and evolution.

Authors:  Patrick Bateson; Peter Gluckman
Journal:  Int J Epidemiol       Date:  2012-02       Impact factor: 7.196

3.  Biological theories, evidence, and epidemiology.

Authors:  David A Leon
Journal:  Int J Epidemiol       Date:  2004-11-26       Impact factor: 7.196

4.  Low birth weight and reduced renal volume in Aboriginal children.

Authors:  J Spencer; Z Wang; W Hoy
Journal:  Am J Kidney Dis       Date:  2001-05       Impact factor: 8.860

Review 5.  Ageing and the glomerular filtration rate: truths and consequences.

Authors:  Richard J Glassock; Christopher Winearls
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

6.  Impaired kidney growth in low-birth-weight children: distinct effects of maturity and weight for gestational age.

Authors:  Ida M Schmidt; Marla Chellakooty; Kirsten A Boisen; Ida N Damgaard; Claudia Mau Kai; Klaus Olgaard; Katharina M Main
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

7.  Fetal origins of adult disease: strength of effects and biological basis.

Authors:  D J P Barker; J G Eriksson; T Forsén; C Osmond
Journal:  Int J Epidemiol       Date:  2002-12       Impact factor: 7.196

8.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28

Review 9.  Fetal origins of adult disease-the hypothesis revisited.

Authors:  A Lucas; M S Fewtrell; T J Cole
Journal:  BMJ       Date:  1999-07-24

10.  Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts.

Authors:  Andrew K Wills; Debbie A Lawlor; Fiona E Matthews; Avan Aihie Sayer; Eleni Bakra; Yoav Ben-Shlomo; Michaela Benzeval; Eric Brunner; Rachel Cooper; Mika Kivimaki; Diana Kuh; Graciela Muniz-Terrera; Rebecca Hardy
Journal:  PLoS Med       Date:  2011-06-14       Impact factor: 11.069

View more
  1 in total

1.  Indicators of fetal growth and adult liver enzymes: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study.

Authors:  E W Harville; W Chen; L Bazzano; M Oikonen; N Hutri-Kähönen; O Raitakari
Journal:  J Dev Orig Health Dis       Date:  2016-12-06       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.